-+ 0.00%
-+ 0.00%
-+ 0.00%

ATEA PHARMACEUTICALS PRESENTS NEW DRUG-DRUG INTERACTION RESULTS SUPPORTING POTENTIAL BEST-IN-CLASS PROFILE OF THE REGIMEN OF BEMNIFOSBUVIR AND RUZASVIR FOR THE TREATMENT OF HEPATITIS C VIRUS AT EASL CONGRESS 2026

Reuters·05/27/2026 11:00:03

Please log in to view news